Cell Source Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cell Source Inc's ROI in the first quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Cell Source Inc 's return on investment (ROI) in its first quarter of 2025

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Investment Change TTM	-	-11.36 %	-28.79 %	2.13 %	-20.09 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	-6	0	0	0	0
Return On Investment (TTM)	-	-1697.25 %	-2152.36 %	-1890.24 %	-2410.74 %
CLCS's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-	9.39 %	-9.13 %	22.62 %	-27.28 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-5	-5	-5	-5	-5

CLCS Company Profile >> Back to CLCS Roi Comparisons >> See Annual CLCS Return On Investment

Return On Investment CLCS's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Cell Source Inc's I. Quarter Investments	$ -6 Millions	CLCS's Balance sheet
Cell Source Inc's I. Quarter Income	$ -1 Millions	Quarterly CLCS's Income Statement
CLCS's Income by Division		See CLCS's Income by Division

CLCS Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	0	0	0	-10	-8
Y / Y Investment Growth	46.79 %	-52.38 %	-	-	-
Net Income in Millions	-5	-5	-5	-5	-5
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-1575.09 %	-2726.44 %	-1260.9 %	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CLCS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CLCS's Competitors
Subscribers only: Roi for Cell Source Inc's Suppliers
Subscribers only: Return On Investment for CLCS's Customers

Other Ratios
CLCS's Roa	CLCS's Inventory Turnover Ratio	CLCS's Growth Rates	CLCS's Dividend Statistics
	CLCS's Profitability Ratios	CLCS's Asset Turnover Ratio	CLCS's Dividend Growth
CLCS's Roe	CLCS's Valuation Ratios	CLCS's Financial Strength Ratios	CLCS's Dividend Payout Ratio

Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector	ROI
Traws Pharma inc	1,014.38 %
Inhibrx Biosciences Inc	935.29 %
Capforce Inc	322.66 %
Pavmed Inc	314.73 %
Interpace Biosciences Inc	213.95 %
Cytomx Therapeutics Inc	139.64 %
Camp4 Therapeutics Corporation	136.24 %
Alumis inc	113.83 %
Stablecoin Development Corporation	110.75 %
Earth Science Tech Inc	100.58 %
Oak Woods Acquisition Corp	93.88 %
Avalo Therapeutics Inc	88.86 %
Tao Synergies Inc	78.95 %

Date modified: 2026-09-08T15:11:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.